I always find it intriguing how the introduction of new therapies can drive research directions. In this edition of the journal we have several papers on atrial fibrillation (AF). There is no doubt that the introduction of the novel oral anticoagulants (NOACS) is one of the most significant advances in stroke prevention over the last few decades. This is currently driving such studies as presented by Toyoda et al., with the SAMURAI-NVAF STUDY. The investigators showed that in Japan from 2011 to 2014 the introduction of NOACS had been gradually increasing, although they tended to be used in patients with milder stroke deficits and lower risk index scores. The continuation of studies like this will be important to document the increasing use of NOACS in real world practice and their risks compared to warfarin use. As a backdrop to this we also see NOACS driving a renewed interest in the natural history of AF risk, particularly around the question of what duration of AF constitutes increased stroke risk. The systematic review and meta-analysis of Sposato et al. emphasizes there is no real evidence of risk for AF, duration of thirty seconds or less. Clearly, the opportunity exists to do much more research in this area using long-term implantable devices.
The other new therapy driving changes in stroke research directions is the new endovascular wave. Already organizations around the world are altering their clinical guidelines to cope with what is going to be a very rapidly moving field. We are pleased to bring to you one of the earliest of these, the Canadian Stroke Best Practice Recommendations: Hyperacute Stroke Care Guidelines, Update 2015.
Other interesting papers in this edition are those using large databases to provide useful predictive models for clinical practice. These large databases are a relatively new phenomenon and are likely to increase in number and volume. For example, Flint et al. used the Vista and SITS MOST databases of more than 12,000 patients to validate the THIVE-C as a predictive tool for stroke outcome from baseline variables. Correspondingly, Cooray et al. used the SITS-ISTR of more than 44,000 patients to develop predictors of baseline vessel occlusion and subsequent functional independence. Their finding of baseline NIHSS of 11 and 12, respectively, is clinical useful, particularly for the conduct of future trials.
On a more sombre note, we were saddened to hear of the recent passing of Dr. Jack P. Whisnant. As everyone knows in the stroke community, Jack was a giant in the field and one of its greatest pioneers. After seeing hostilities as a pilot in the Pacific theatre of WWII he later completed his neurology training and became one of the early investigators in stroke mechanism and epidemiology, while rising to head the division of neurology of the Mayo Clinic. His unassuming style inspired a generation of neurologists, with landmark epidemiological studies emanating from Onsted County. Among his many leadership positions he was president of both the American Neurological Association and the American Academy of Neurology. His loss will be felt keenly around the globe. Vale one of the greats.
